Literature DB >> 30367311

Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics.

Rebecca Haberman1, Lourdes M Perez-Chada2, Joseph F Merola3, Jose Scher1, Alexis Ogdie4, Soumya M Reddy5.   

Abstract

PURPOSE OF REVIEW: Despite a robust therapeutic landscape, significant gaps exist in the quality of care of psoriatic disease. Thus, an improved understanding of the challenges in providing quality care and the implementation of effective strategies to overcome them is needed. In this review, we summarize the burden of psoriatic disease, discuss the challenges in the care of psoriatic patients, and outline how combined dermatology-rheumatology clinics bridge many of these gaps. RECENT
FINDINGS: Multiple challenges are faced in providing high-quality care to patients with psoriasis and psoriatic arthritis from the pre-diagnosis phase of disease to the follow-up period. Challenges are mainly driven by lack of education of patients and healthcare providers, inefficient communication between specialists, lack of a holistic approach to patients, and limitations of available therapies. The Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) is working on demonstrating the effectiveness of combined dermatology-rheumatology clinics in addressing some of these challenges. Recent findings show that combined clinic models may improve quality of care by raising awareness of psoriatic disease, fostering educational activities for both patients and physicians, and allowing for comprehensive evaluation and management of patients through improved communications between disciplines. Psoriasis and psoriatic arthritis are complex diseases that often require an interdisciplinary approach. Thus, combined dermatology-rheumatology clinics and local-regional partnerships are potentially effective in improving quality of care in psoriatic disease.

Entities:  

Keywords:  Interdisciplinary communication; Psoriasis; Psoriatic arthritis; Quality of healthcare

Mesh:

Year:  2018        PMID: 30367311     DOI: 10.1007/s11926-018-0785-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  72 in total

1.  Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.

Authors:  Philip J Mease; Dafna D Gladman; Kim A Papp; Majed M Khraishi; Diamant Thaçi; Frank Behrens; Robert Northington; Joanne Fuiman; Eustratios Bananis; Robert Boggs; Daniel Alvarez
Journal:  J Am Acad Dermatol       Date:  2013-08-24       Impact factor: 11.527

Review 2.  The psychosocial burden of psoriasis.

Authors:  Alexa B Kimball; Christine Jacobson; Stefan Weiss; Mary G Vreeland; Ying Wu
Journal:  Am J Clin Dermatol       Date:  2005       Impact factor: 7.403

Review 3.  Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis.

Authors:  Axel Patrice Villani; Marie Rouzaud; Morgane Sevrain; Thomas Barnetche; Carle Paul; Marie-Aleth Richard; Marie Beylot-Barry; Laurent Misery; Pascal Joly; Michel Le Maitre; Selim Aractingi; François Aubin; Alain Cantagrel; Jean-Paul Ortonne; Denis Jullien
Journal:  J Am Acad Dermatol       Date:  2015-06-06       Impact factor: 11.527

4.  Risk of depression in women with psoriasis: a cohort study.

Authors:  E D Dommasch; T Li; O I Okereke; Y Li; A A Qureshi; E Cho
Journal:  Br J Dermatol       Date:  2015-09-24       Impact factor: 9.302

5.  Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis.

Authors:  Prashanth Sunkureddi; Stephen Doogan; John Heid; Samir Benosman; Alexis Ogdie; Layne Martin; Jacqueline B Palmer
Journal:  J Rheumatol       Date:  2018-02-15       Impact factor: 4.666

6.  Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis.

Authors:  Sıdıka Gülkan Özkan; Hatice Yazısız; Ahmet Behlül; Yüksel Aslı Gökbelen; Fatih Borlu; Veli Yazısız
Journal:  Eur J Rheumatol       Date:  2017-03-01

7.  Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting.

Authors:  Guillaume Favier; Dafna D Gladman; Joseph F Merola; April W Armstrong; Wolf Henning Boehncke; Philip S Helliwell
Journal:  J Rheumatol       Date:  2017-05       Impact factor: 4.666

8.  One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic.

Authors:  Andreas Storm; Stig Ejdrup Andersen; Eva Benfeldt; Jørgen Serup
Journal:  J Am Acad Dermatol       Date:  2008-05-07       Impact factor: 11.527

9.  Depression and anxiety in psoriatic disease: prevalence and associated factors.

Authors:  Emily McDonough; Renise Ayearst; Lihi Eder; Vinod Chandran; Cheryl F Rosen; Arane Thavaneswaran; Dafna D Gladman
Journal:  J Rheumatol       Date:  2014-04-01       Impact factor: 4.666

10.  The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

Authors:  Shanu Kohli Kurd; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2008-11-20       Impact factor: 11.527

View more
  4 in total

1.  Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States.

Authors:  Alexis Ogdie; W Benjamin Nowell; Eddie Applegate; Kelly Gavigan; Shilpa Venkatachalam; Marie de la Cruz; Emuella Flood; Ethan J Schwartz; Beverly Romero; Peter Hur
Journal:  BMC Rheumatol       Date:  2020-01-10

2.  Effectiveness of interdisciplinary combined dermatology-gastroenterology-rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial.

Authors:  Kasper Fjellhaugen Hjuler; Anders Dige; Jørgen Agnholt; Trine Bay Laurberg; Anne Gitte Loft; Louise Faurskov Møller; Robin Christensen; Lars Iversen
Journal:  BMJ Open       Date:  2021-04-28       Impact factor: 2.692

Review 3.  Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study.

Authors:  Lourdes M Perez-Chada; Rebecca H Haberman; Joseph F Merola; Jose U Scher; Vinod Chandran; Cheryl F Rosen; Christopher Ritchlin; Lihi Eder; Philip Mease; Soumya Reddy; Alexis Ogdie
Journal:  Nat Rev Rheumatol       Date:  2021-02-15       Impact factor: 20.543

4.  TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA).

Authors:  Nienke J Kleinrensink; Frank T Perton; Juliëtte N Pouw; Nanette L A Vincken; Sarita A Y Hartgring; Mylène P Jansen; Saeed Arbabi; Wouter Foppen; Pim A de Jong; Janneke Tekstra; Emmerik F A Leijten; Julia Spierings; Floris P J G Lafeber; Paco M J Welsing; Marloes W Heijstek
Journal:  BMJ Open       Date:  2022-10-10       Impact factor: 3.006

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.